Abstract

Tryptophan-rich proteins from several malarial parasites have been identified where they play an important role in host-parasite interaction. Structural characterization of these proteins is needed to develop them as therapeutic targets. Here, we describe a novel Plasmodium vivax tryptophan-rich protein named PvTRAg33.5. It is expressed by blood stage(s) of the parasite and its gene contains two exons. The exon 1 encodes for a 23 amino acids long putative signal peptide which is likely to be cleaved off whereas the exon 2 encodes for the mature protein of 252 amino acids. The mature protein contains B-cell epitopes which were recognized by the human immune system during P.vivax infection. The PvTRAg33.5 contains 24 (9.5%) tryptophan residues and six motifs whose patterns were similar among tryptophan-rich proteins. The modeled structure of the PvTRAg33.5 consists of a multidomain architecture which is stabilized by the presence of large number of tryptophan residues. The recombinant PvTRAg33.5 showed predominantly α helical structure and alpha helix to beta sheet transition at pH below 4.5. Protein acquires an irreversible non-native state at temperature more than 50°C at neutral pH. Its secondary and tertiary structures remain stable in the presence of 35% alcohol but these structures are destabilized at higher alcohol concentrations due to the disturbance of hydrophobic interactions between tryptophanyl residues. These structural changes in the protein might occur during its translocation to interact with other proteins at its final destination for biological function such as erythrocyte invasion.

Highlights

  • Malaria remains uncontrolled to date and requires effective antimalarial drugs and vaccines [1]

  • Sequence analysis of the pvtrag33.5 gene Homology searches for the tryptophan-rich antigen of P. vivax identified a number of related protein molecules in the Plasmodium database

  • We describe here the structural characteristic features of a tryptophan- rich antigen (PvTRAg33.5)

Read more

Summary

Introduction

Malaria remains uncontrolled to date and requires effective antimalarial drugs and vaccines [1]. Vaccine and drug development strategies require identification and characterization of the target molecules. The parasite molecules which interact with the host molecules are good drug or vaccine targets. This is because any molecule or antibody which can disrupt this host - parasite molecular interaction can be used as therapeutic reagent to interrupt the disease progression. In comparison to the Plasmodium falciparum, only fewer vaccine/drug target molecules of P.vivax have been identified because of its non-cultivable nature this parasite affects large number of people in tropical countries and sometime can cause severe complications in humans [1,2,3]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call